Liver damage in patients with ischemic chronic heart and type 2 diabetes - a treacherous tandem: possible additional organoprotective therapy

Cover Page

Cite item

Full Text

Abstract

The presented data on the structure and functional state of the liver in patients with ischemic chronic heart failure (CHF) and type 2 diabetes. Showcased additional opportunities organoprotective (hepato-, cardioprotective) taurine therapy in combination therapy in patients with CHF and type 2 diabetes. Noted additional hypoglycemic, lipid-lowering capabilities of taurine, a positive effect on the severity of insulin resistance.

About the authors

M. E Statsenko

Volgograd State Medical University of Ministry of Health of the Russian Federation

Email: mestatsenko@rambler.ru
д-р мед. наук, проф., зав. каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

S. V Turkina

Volgograd State Medical University of Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

N. N Shilina

Volgograd State Medical University of Ministry of Health of the Russian Federation

канд. мед. наук, ассистент каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

References

  1. Nieminen M.S, Brutsaert D, Dickstein K et al. Euro Heart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36.
  2. Bertoni A.G, Hundley W.G, Massing M.W et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
  3. Sarma S, Mentz R.J, Kwasny M.J et al. On behalf of the EVEREST investigators. Association between diabetes mellitus and post - discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194-202.
  4. Shengbo Y. The prevalence and prognostic value of liver function abnormalities in patients with chronic systolic heart failure. Heart 2011; 97: А215.
  5. Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1724-45.
  6. Ekstedt M, Franz´en L.E, Mathiesen U.L et al. Long - term follow - up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
  7. Dogan S, Celikbilek M, Yilmaz Y.K et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 298-304.
  8. Kim D, Kim W.R, Kim H.J, Terry M. Therneau. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (Issue 4): 1357-65.
  9. Ban C.R, Twigg S.M. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575-96.
  10. Dries D.L, Sweitzer N.K, Drazner M.H et al. Prognostic Impact of Diabetes Mellitus in Patients With Heart Failure According to the Etiology of Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2001; 38 (2): 421-8.
  11. Xu Y.J, Saini H.K, Zhang M et al. MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res 2006; 72: 163-74.
  12. Schaffer S.W, Lombardini J.B, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000; 18: 305-18.
  13. Abebe W, Mozaffari M.S. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 2011; 1 (3): 293-311.
  14. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Винникова А.А. Место таурина в комплексном лечении пациентов с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Рус. мед. журн. 2015; 23 (8): 472-6.
  15. Abd El-Kader S.M, El-Den Ashmaw E.M.S. Non - alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7 (6): 846-58.
  16. Gentile C.L, Nivala A.M, Gonzales J.C et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011; 301 (6): R1710-R1722.
  17. Balkan J, Do ru-Abbaso lu S, Kanba li O et al. Taurine has a protective effect against thioacetamide - induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 2001; 20: 251-4.
  18. Hansen S.H. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001; 17: 330-46.
  19. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Косивцова М.А. Особенности гепато - кардиальных взаимоотношений у пациентов с хронической сердечной недостаточностью и нарушениями углеводного обмена: возможности дополнительной терапии. Рус. мед. журн. 2015; 23 (21): 1293-7.
  20. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7 (81): 1-94.
  21. Алгоритмы специализированной медицинской помощи больным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2015.]
  22. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33-8.
  23. Angulo P, Hui J.M, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846-54.
  24. Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek 2011; 68 (6): 334-8.
  25. EASL-ALEH Clinical Practice Guidelines: Non - invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 1. doi: 10.1016/j.jhep.2015.04.006.
  26. Yokogoshi H, Mochizuki H, Nanami K et al. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high - cholesterol diet. J Nutr 1999; 129: 1705-12.
  27. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke - prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303-13.
  28. Unger R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398-403.
  29. Carneiro E.M, Latorraca M.Q, Araujo E et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochemistry 2009; 20: 503-11.
  30. Maturo J, Kulakowski E.C. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37 (19): 3755-60.
  31. Gavrovskaya L.K, Ryzhova O.V, Safonova A.F et al. Protective effect of taurine on rats with experimental insulin - dependent diabetes mellitus. Bull Exp Biol Med 2008; 146 (2): 226-8.
  32. Nakaya Y, Minami A, Harada N et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71 (1): 54-8.
  33. Wu N, Lu Y, He B et al. Taurine prevents free fatty acid - induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo Diabetes Res Clin Pract 2010; 90 (3): 288-96.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies